Mesoblast Ltd. (MESO) Downgraded by Zacks Investment Research
Mesoblast Ltd. (NASDAQ:MESO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “
Separately, Maxim Group reissued a “buy” rating and set a $14.00 price target on shares of Mesoblast in a report on Wednesday, July 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $8.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/mesoblast-ltd-meso-downgraded-by-zacks-investment-research.html
Mesoblast (NASDAQ:MESO) opened at 4.18 on Wednesday. Mesoblast has a 12-month low of $3.50 and a 12-month high of $13.00. The stock has a 50 day moving average price of $4.53 and a 200-day moving average price of $5.75. The company’s market cap is $315.90 million.
Large investors have recently bought and sold shares of the company. Citigroup Inc. raised its stake in Mesoblast by 659,900.0% in the second quarter. Citigroup Inc. now owns 33,000 shares of the company’s stock valued at $131,000 after buying an additional 32,995 shares during the period. Princeton Capital Management Inc. raised its stake in Mesoblast by 135.4% in the second quarter. Princeton Capital Management Inc. now owns 109,382 shares of the company’s stock valued at $433,000 after buying an additional 62,915 shares during the period. OLD Mission Capital LLC bought a new stake in Mesoblast during the first quarter valued at approximately $431,000. Finally, Prudential PLC raised its stake in Mesoblast by 2.0% in the first quarter. Prudential PLC now owns 1,538,629 shares of the company’s stock valued at $14,802,000 after buying an additional 29,597 shares during the period. Hedge funds and other institutional investors own 3.41% of the company’s stock.
Mesoblast Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.